PVLA Stock Summary and Trading Ideas (Palvella Therapeutics | NASDAQ:PVLA)

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Palvella Therapeutics trades on the NASDAQ stock market under the symbol PVLA.

As of February 19, 2026, PVLA stock price climbed to $82.33 with 497,929 million shares trading.

PVLA has a beta of 0.38, meaning it tends to be less sensitive to market movements. PVLA has a correlation of 0.01 to the broad based SPY ETF.

PVLA has a market cap of $974.50 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that PVLA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

PVLA has outperformed the market in the last year with a price return of +292.2% while the SPY ETF gained +13.1%. However, in the short term, PVLA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -0.7% vs +4.0% return in SPY. But in the last 2 weeks, PVLA shares have fared better than the market returning +0.4% compared to SPY -0.2%.

PVLA support price is $75.72 and resistance is $83.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PVLA shares will trade within this expected range on the day.